Mesoporous silica nanoparticles for reducing hemolytic activity towards mammalian red blood cells.
about
Nanomaterials in humans: identification, characteristics, and potential damageAerosol droplet delivery of mesoporous silica nanoparticles: a strategy for respiratory-based therapeuticsChemical basis of interactions between engineered nanoparticles and biological systemsIn Vivo Integrity and Biological Fate of Chelator-Free Zirconium-89-Labeled Mesoporous Silica Nanoparticles.The safety of nanostructured synthetic amorphous silica (SAS) as a food additive (E 551)Microsomal glutathione transferase 1 protects against toxicity induced by silica nanoparticles but not by zinc oxide nanoparticlesMesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibilityThe nanosilica hazard: another variable entity.Processing pathway dependence of amorphous silica nanoparticle toxicity: colloidal vs pyrolyticDifferential expression of syndecan-1 mediates cationic nanoparticle toxicity in undifferentiated versus differentiated normal human bronchial epithelial cellsReduction of Acute Inflammatory Effects of Fumed Silica Nanoparticles in the Lung by Adjusting Silanol Display through Calcination and Metal DopingAmine modification of nonporous silica nanoparticles reduces inflammatory response following intratracheal instillation in murine lungsOrganically modified silica nanoparticles are biocompatible and can be targeted to neurons in vivoNon-metallic nanomaterials in cancer theranostics: a review of silica- and carbon-based drug delivery systemsAspect ratio determines the quantity of mesoporous silica nanoparticle uptake by a small GTPase-dependent macropinocytosis mechanism.One-step synthesis of water-dispersible ultra-small Fe3O4 nanoparticles as contrast agents for T1 and T2 magnetic resonance imaging.Acidic pH-targeted chitosan capped mesoporous silica coated gold nanorods facilitate detection of pancreatic tumors via multispectral optoacoustic tomographyDirect intercalation of cisplatin into zirconium phosphate nanoplatelets for potential cancer nanotherapy.Silica nanoparticles as a delivery system for nucleic acid-based reagents.Visualisation of sentinel lymph node with indium-based near infrared emitting Quantum Dots in a murine metastatic breast cancer model.Synthesis and surface functionalization of silica nanoparticles for nanomedicineMultifunctional core/shell nanoparticles cross-linked polyetherimide-folic acid as efficient Notch-1 siRNA carrier for targeted killing of breast cancerRenal interstitial fibrosis induced by high-dose mesoporous silica nanoparticles via the NF-κB signaling pathway.Tissue distribution and excretion kinetics of orally administered silica nanoparticles in rats.Graphene oxide/manganese ferrite nanohybrids for magnetic resonance imaging, photothermal therapy and drug delivery.Haemocompatibility evaluation of silica nanomaterials using hemorheological measurements.Promising plasmid DNA vector based on APTES-modified silica nanoparticlesFabrication of RGD-conjugated Gd(OH)3:Eu nanorods with enhancement of magnetic resonance, luminescence imaging and in vivo tumor targeting.Enhanced Blood Suspensibility and Laser-Activated Tumor-specific Drug Release of Theranostic Mesoporous Silica Nanoparticles by Functionalizing with Erythrocyte Membranes.Hemopexin as biomarkers for analyzing the biological responses associated with exposure to silica nanoparticles.Oxidative Damage and Energy Metabolism Disorder Contribute to the Hemolytic Effect of Amorphous Silica Nanoparticles.Nanostructured porous Si-based nanoparticles for targeted drug deliveryProtocells: Modular Mesoporous Silica Nanoparticle-Supported Lipid Bilayers for Drug Delivery.Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model.Smart Mesoporous Nanomaterials for Antitumor Therapy.Mesoporous silica nanoparticles for intracellular controlled drug delivery.Capped mesoporous silica nanoparticles as stimuli-responsive controlled release systems for intracellular drug/gene delivery.Physico-chemical features of engineered nanoparticles relevant to their toxicity.Mesoporous silica nanoparticles as nanocarriers.Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery.
P2860
Q23924128-085A7ECF-A590-47EA-9E2F-61AD338FABA5Q26343130-B3C6ED39-8451-492D-B38F-2DC0BEDC2D89Q27021154-1544AD53-D1A7-4F3C-9CF9-C3E73948E32EQ27342269-DB778C2B-1B56-405B-AE24-4F750349A5E1Q28079029-CA0A99D3-56E6-4A2A-AA85-8B6D37537D29Q28382868-96C054E6-D5E6-4C5A-ACD6-FC373007F321Q28384598-852C5CB1-22A6-452F-99DB-1DCAE2CDF365Q28385555-216EBBF1-CFB5-4718-88E0-D1E91E3B9BB1Q28391345-678DC4BB-ACE4-4D28-B711-77DA13BDC794Q28394538-502B3452-F031-4747-9718-5E82B0E01827Q28397187-6D2A2C54-27C7-4FDD-BE24-A27FA149BB40Q28397622-3DB8AA60-A056-4E40-B0A5-0A1009306C24Q28478671-C8E13373-C780-4ADF-B711-FCD9D5B1B227Q28822460-84FFE83A-F1F4-469F-9923-314D3FFA5134Q30501687-BB213ACE-5A88-4653-9F6F-B9B497AFE695Q30746227-C68940C1-0F76-4F9D-9775-83DDE063E36BQ30855722-BFA6B75E-5225-4BD3-ABC0-1246BBCE0F91Q34075557-54562428-67BB-4560-A884-38EBA0E828D4Q34080775-4CF718CF-C9D8-4ED2-A8F3-3BC19F56BE1BQ34406736-B9A82F19-6FD3-4B02-BF36-3B4E50E227F2Q34417407-1908DBBC-E599-48E1-A78E-46FB02DAFD9AQ34519604-61C91A7A-9BD2-4022-B60C-FAEE2628D31EQ34763969-0664B91A-F74D-4656-812E-59D046C0BD07Q34787883-C19D7B32-A138-49D6-B46B-0E501006E0BCQ35752719-0F5833EA-2557-4481-94D5-D4AED5A81C9BQ35789664-A9BF55AA-F6B8-4916-851A-CAD13A795C3FQ35797545-8A6621F6-5729-41E9-A3E7-DA424486E2ECQ36155576-13289893-F5A6-4145-9B64-4D881CAE6C4CQ36296097-BE4E61DA-2A88-4823-B312-7BCCF20CF78BQ36368022-5326C64B-5644-42CD-8FFF-8D626B06F109Q36526580-BEA378DE-A6BA-42C4-99DF-D0E05817FF89Q36597461-C5EA52A0-1CEC-41E5-87C2-5ACF97D7FD01Q37134029-E4162DD4-E9C2-47E4-9AEC-0131A95C8E72Q37529131-414ACA5D-8099-4731-A51A-07734876E5FDQ37638621-7E8B0E3A-6AD8-432A-80AE-055DBA67C2E9Q37778327-07892D04-1A3A-4F8F-BBF3-2B89FCD664C5Q37780545-F10EA5A9-350D-453A-B9D1-3BFE68F14490Q37790699-3082C18C-819C-4023-9934-3CE88055A542Q37895950-D63745EF-D254-4F85-BB3C-5CCE40EBD404Q37989408-8ABD9314-3305-4047-B68F-4B52010F11EA
P2860
Mesoporous silica nanoparticles for reducing hemolytic activity towards mammalian red blood cells.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Mesoporous silica nanoparticle ...... rds mammalian red blood cells.
@en
Mesoporous silica nanoparticle ...... rds mammalian red blood cells.
@nl
type
label
Mesoporous silica nanoparticle ...... rds mammalian red blood cells.
@en
Mesoporous silica nanoparticle ...... rds mammalian red blood cells.
@nl
prefLabel
Mesoporous silica nanoparticle ...... rds mammalian red blood cells.
@en
Mesoporous silica nanoparticle ...... rds mammalian red blood cells.
@nl
P2093
P356
P1433
P1476
Mesoporous silica nanoparticle ...... rds mammalian red blood cells.
@en
P2093
Igor I Slowing
Juan L Vivero-Escoto
Victor S-Y Lin
P356
10.1002/SMLL.200800926
P50
P577
2009-01-01T00:00:00Z